These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 24346286

  • 1. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment.
    Park YH, Jung HA, Choi MK, Chang W, Choi YL, Do IG, Ahn JS, Im YH.
    Br J Cancer; 2014 Jan 21; 110(2):384-91. PubMed ID: 24346286
    [Abstract] [Full Text] [Related]

  • 2. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA.
    BMC Cancer; 2019 May 30; 19(1):517. PubMed ID: 31146717
    [Abstract] [Full Text] [Related]

  • 3. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.
    Cancer Chemother Pharmacol; 2013 Jul 30; 72(1):109-15. PubMed ID: 23673443
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tural D, Serdengecti S, Demirelli F, Öztürk T, İlvan S, Turna H, Özgüroglu M, Büyükünal E.
    Br J Cancer; 2014 Apr 15; 110(8):1968-76. PubMed ID: 24595002
    [Abstract] [Full Text] [Related]

  • 5. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
    Kim JW, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.
    Cancer Chemother Pharmacol; 2013 Nov 15; 72(5):1023-9. PubMed ID: 24036907
    [Abstract] [Full Text] [Related]

  • 6. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR.
    J Clin Oncol; 2015 May 10; 33(14):1574-83. PubMed ID: 25779558
    [Abstract] [Full Text] [Related]

  • 7. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT.
    Oncologist; 2019 Aug 10; 24(8):e646-e652. PubMed ID: 30602614
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
    Bergin ART, Luen SJ, Savas P, Boolell V, Cho D, Lynch J, Nott L, Stuart-Harris R, Teo LN, Yap SY, Loi S.
    Asia Pac J Clin Oncol; 2019 Dec 10; 15(6):377-382. PubMed ID: 31321873
    [Abstract] [Full Text] [Related]

  • 9. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS, Sohn J, Kim SI, Park S, Park HS, Gho SG, Chung HC, Paik S, Kim GM.
    Breast Cancer Res Treat; 2017 Jun 10; 163(2):255-262. PubMed ID: 28243895
    [Abstract] [Full Text] [Related]

  • 10. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K, Kashiwagi S, Goto W, Asano Y, Morisaki T, Fujita H, Takashima T, Ohsawa M, Hirakawa K, Ohira M.
    Anticancer Res; 2018 Apr 10; 38(4):2285-2294. PubMed ID: 29599351
    [Abstract] [Full Text] [Related]

  • 11. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
    J Clin Oncol; 2013 May 10; 31(14):1719-25. PubMed ID: 23569311
    [Abstract] [Full Text] [Related]

  • 12. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS.
    Oncologist; 2013 May 10; 18(5):501-10. PubMed ID: 23652380
    [Abstract] [Full Text] [Related]

  • 13. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K.
    Oncology; 2017 May 10; 93(1):51-61. PubMed ID: 28478451
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.
    J Clin Oncol; 2012 Sep 10; 30(26):3234-41. PubMed ID: 22649126
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.
    Dębska-Szmich S, Kusińska R, Czernek U, Szydłowska-Pazera K, Habib-Lisik M, Piekarski JH, Olas E, Kulig A, Ułańska M, Kalinka-Warzocha E, Potemski P.
    Postepy Hig Med Dosw (Online); 2015 May 05; 69():586-97. PubMed ID: 25983297
    [Abstract] [Full Text] [Related]

  • 16. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA.
    Cancer; 2019 Nov 15; 125(22):3974-3984. PubMed ID: 31318460
    [Abstract] [Full Text] [Related]

  • 17. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
    Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, Gong G, Son BH, Ahn SH, Jung KH.
    Tumour Biol; 2015 Aug 15; 36(8):5865-71. PubMed ID: 25725586
    [Abstract] [Full Text] [Related]

  • 18. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
    Rier HN, Levin MD, van Rosmalen J, Bos MMEM, Drooger JC, de Jong P, Portielje JEA, Elsten EMP, Ten Tije AJ, Sleijfer S, Jager A.
    Oncologist; 2017 Aug 15; 22(8):901-909. PubMed ID: 28533475
    [Abstract] [Full Text] [Related]

  • 19. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
    Xie BJ, Zhu LN, Ma C, Li JB, Dong L, Zhu ZN, Ding T, Gu XS.
    Breast Cancer; 2020 Mar 15; 27(2):186-196. PubMed ID: 31529262
    [Abstract] [Full Text] [Related]

  • 20. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
    Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X.
    BMC Cancer; 2011 Jun 15; 11():248. PubMed ID: 21676217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.